These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19839939)

  • 1. Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.
    Götz J; Götz NN
    ASN Neuro; 2009 Nov; 1(4):. PubMed ID: 19839939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy.
    Götz J; Streffer JR; David D; Schild A; Hoerndli F; Pennanen L; Kurosinski P; Chen F
    Mol Psychiatry; 2004 Jul; 9(7):664-83. PubMed ID: 15052274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head to head comparison of [
    Jang YK; Lyoo CH; Park S; Oh SJ; Cho H; Oh M; Ryu YH; Choi JY; Rabinovici GD; Kim HJ; Moon SH; Jang H; Lee JS; Jagust WJ; Na DL; Kim JS; Seo SW
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):432-442. PubMed ID: 29143870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau and transgenic animal models.
    Götz J
    Brain Res Brain Res Rev; 2001 Jul; 35(3):266-86. PubMed ID: 11423157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease.
    Le Bouc R; Lenfant P; Delbeuck X; Ravasi L; Lebert F; Semah F; Pasquier F
    Brain; 2012 Oct; 135(Pt 10):3026-38. PubMed ID: 23065791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of Alzheimer's disease and frontotemporal dementia.
    Götz J; Ittner LM
    Nat Rev Neurosci; 2008 Jul; 9(7):532-44. PubMed ID: 18568014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
    Reddy PH; Oliver DM
    Cells; 2019 May; 8(5):. PubMed ID: 31121890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.
    Zhou J; Greicius MD; Gennatas ED; Growdon ME; Jang JY; Rabinovici GD; Kramer JH; Weiner M; Miller BL; Seeley WW
    Brain; 2010 May; 133(Pt 5):1352-67. PubMed ID: 20410145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Kayed R
    Immunotargets Ther; 2014; 3():19-28. PubMed ID: 27471697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET and amyloid-PET imaging: the diverging paths.
    Perani D
    Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.